



March 16, 2017

Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presentations

First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program

DANVERS, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- [Abiomed, Inc.](#) (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 10 presentations, including a late-breaking clinical research presentation, featuring the Impella® line of heart pumps, in addition to 17 poster presentations scheduled during the American College of Cardiology's 66th Annual Scientific Session, March 17-19 at the Walter E. Washington Convention Center in Washington, DC.

Abiomed is committed to improving outcomes in Protected PCI and cardiogenic shock through technology and innovation, excellence in education, clinical research, and appropriate and standardized use. The following initiatives are planned for ACC:

- ▮ **Featured Clinical Research: Outcomes for 15,259 Patients with Acute MI Cardiogenic Shock (AMICS) supported with Impella devices and early results from unprecedented collaboration in Detroit**
On Sunday, March 19th at 2:00 PM, Dr. William O'Neill of Henry Ford Health System will present new data from the Impella Quality (IQ) Assurance Program, an initiative designed to improve outcomes in Protected PCI and cardiogenic shock. One component of the program is Abiomed's IQ Database, a real-world collection of clinical information derived from the treatment of patients with Impella devices over the past eight years. This observational data, combined with clinical data collected in the cVAD Registry and FDA pre- and post-market studies, is used to develop clinical protocols by highlighting the best practices associated with superior, real-world outcomes.
- ▮ **Detroit Cardiogenic Shock Initiative (DCSI)**
Leveraging best practices and protocols from Abiomed Impella Quality (IQ) Assurance Program, Dr. O'Neill will share early results and new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented partnership between five competitive hospital systems in metro Detroit with the goal of determining whether outcomes in cardiogenic shock can be improved with best practice protocols, including early use of Impella before PCI. These protocols are based on data derived from the IQ Database and top performing hospitals in Detroit.
- ▮ **Abiomed Booth Activities**
Abiomed's booth #2427 will feature daily demonstrations and opportunities for physicians to engage in hands-on simulations of the Impella platform with new simulator updates. Abiomed's product specialists will discuss new technologies and innovations.
- ▮ **Potential Live Cases Utilizing Impella Devices**
Abiomed anticipates the potential broadcast of several live cases utilizing Impella devices from participating sites. Further details regarding these live cases will be announced the day of the scheduled procedures, as patient status is subject to change.

The schedule for ACC symposia is included below. Additional Impella-related presentations and poster sessions are anticipated.

The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP)

Marriott Marquis, Marquis Ballroom, Salon 5, Level M2

Thursday, March 16 | 6:30-9:00 PM

Chairs:

Navin K. Kapur, MD

William L. Lombardi, MD

James M. McCabe, MD

Ajay J. Kirtane, MD, SM

A Changing Approach to Percutaneous Hemodynamic Support: Decisions, Devices and Results

Marriott Marquis, Marquis Ballroom, Salon 5, Level M2

Saturday, March 18 | 6:15-7:45 AM

Faculty:

Navin K. Kapur, MD

William O'Neill, MD

Ajay Srivastava, MD
Eric Velazquez, MD

ABOUT IMPELLA HEART PUMPS

The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.

The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

**For further information please contact:

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com

Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com